Rubicon Research Share Price Today: Stock Lists at ₹620, Up 28% from IPO Price on NSE, BSE – Check Listing Gains, GMP and Key Details

Mumbai | October 16

Rubicon Research share price opened at ₹620 on both the NSE and BSE, marking a 27.8% premium over its issue price. The ₹1,377.5 crore Rubicon Research IPO received a remarkable 103.9 times subscription, led by strong institutional and retail participation. Each IPO lot consisted of 30 shares, earning successful investors a listing gain of around ₹18,600 per lot. At the time of listing, the company’s market capitalisation stood close to ₹10,200 crore — a strong start for a mid-sized pharmaceutical player.

Rubicon Research Business and Financial Highlights

The public offer included a fresh issue worth ₹500 crore and an offer for sale (OFS) of ₹877.5 crore by promoter General Atlantic Singapore RR. According to the Red Herring Prospectus (RHP), the company plans to use the proceeds to repay loans of ₹310 crore, fund acquisitions, and support general corporate purposes. Rubicon Research Limited is a pharmaceutical formulation company with a focus on innovation and R&D-led growth. It specialises in drug-device combination products and speciality formulations, catering to regulated markets such as the United States and Canada.

The company operates two R&D centres and two manufacturing units, all approved by regulators including the USFDA, Health Canada, and WHO-GMP. In June 2025, Rubicon acquired Alkem Laboratories’ Pithampur facility for ₹149 crore to strengthen its domestic manufacturing capacity.

GMP, Investor Sentiment and Outlook

Before the listing, Rubicon Research IPO’s grey market premium (GMP) was quoted at around 30% over the issue price, suggesting a healthy debut. While the final listing came slightly below that figure, sentiment remains positive as investors view the company’s focus on research, regulatory compliance, and expansion favourably. Analysts believe that Rubicon’s strong export potential, steady financials, and innovation-led approach position it well in the competitive speciality pharma space. For long-term investors, Rubicon Research could emerge as a reliable compounder, offering exposure to India’s growing pharmaceutical export story.

Bottom Line

The Rubicon Research IPO listing marks one of the stronger pharmaceutical debuts of the season, driven by solid fundamentals and investor confidence. The company’s future performance will depend on its ability to maintain margins, strengthen global presence, and deliver consistent growth. For more IPO listings, stock market updates, and investment insights.